ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. ZEG has an excellent profitability rating, but there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
ZEG had positive earnings in each of the past 5 years.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ZEG (7.31%) is better than 61.54% of its industry peers.
ZEG's Return On Equity of 18.94% is fine compared to the rest of the industry. ZEG outperforms 69.23% of its industry peers.
ZEG's Return On Invested Capital of 14.10% is amongst the best of the industry. ZEG outperforms 80.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 14.50%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.10%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROIC | 14.1% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (14.14%) is better than 65.38% of its industry peers.
ZEG's Profit Margin has improved in the last couple of years.
ZEG has a better Operating Margin (24.05%) than 67.31% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
The Gross Margin of ZEG (82.36%) is better than 82.69% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ZEG has about the same amount of shares outstanding.
Compared to 5 years ago, ZEG has more shares outstanding
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
ZEG has an Altman-Z score of 4.95. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
ZEG has a better Altman-Z score (4.95) than 80.77% of its industry peers.
ZEG has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as ZEG would need 3.46 years to pay back of all of its debts.
ZEG's Debt to FCF ratio of 3.46 is fine compared to the rest of the industry. ZEG outperforms 61.54% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.71) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 4.95 |
ROIC/WACC1.6
WACC8.83%
2.3 Liquidity
A Current Ratio of 0.90 indicates that ZEG may have some problems paying its short term obligations.
The Current ratio of ZEG (0.90) is worse than 76.92% of its industry peers.
ZEG has a Quick Ratio of 0.90. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a Quick ratio of 0.70. This is in the lower half of the industry: ZEG underperforms 73.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.91%, which is quite good.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 15.48% in the last year.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
3.2 Future
The Earnings Per Share is expected to grow by 11.35% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.34% on average over the next years.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.16, ZEG is valued correctly.
ZEG's Price/Earnings ratio is in line with the industry average.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.29, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.34 indicates a correct valuation of ZEG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZEG indicates a somewhat cheap valuation: ZEG is cheaper than 63.46% of the companies listed in the same industry.
ZEG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.74, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.16 | ||
| Fwd PE | 13.34 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 67.31% of the companies listed in the same industry.
ZEG's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.39 | ||
| EV/EBITDA | 22.95 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.29
PEG (5Y)0.87
EPS Next 2Y12.94%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 2.41%. Purely for dividend investing, there may be better candidates out there.
ZEG's Dividend Yield is a higher than the industry average which is at 3.05.
Compared to an average S&P500 Dividend Yield of 2.37, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.41% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
63.60% of the earnings are spent on dividend by ZEG. This is not a sustainable payout ratio.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
FRA:ZEG (7/7/2025, 7:00:00 PM)
119.1
-1.2 (-1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.88%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap369.26B
Analysts82.86
Price Target158.42 (33.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.41% |
Yearly Dividend2.54
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.34%
Min EPS beat(2)-0.63%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.86%
Min EPS beat(4)-1.9%
Max EPS beat(4)9.32%
EPS beat(8)5
Avg EPS beat(8)2.24%
EPS beat(12)9
Avg EPS beat(12)3.68%
EPS beat(16)11
Avg EPS beat(16)2.44%
Revenue beat(2)1
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)-3.08%
PT rev (3m)-6.75%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)-0.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.16 | ||
| Fwd PE | 13.34 | ||
| P/S | 7.88 | ||
| P/FCF | 47.39 | ||
| P/OCF | 33.09 | ||
| P/B | 10.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.95 |
EPS(TTM)7.37
EY6.19%
EPS(NY)8.93
Fwd EY7.5%
FCF(TTM)2.51
FCFY2.11%
OCF(TTM)3.6
OCFY3.02%
SpS15.12
BVpS11.29
TBVpS-4.85
PEG (NY)1.29
PEG (5Y)0.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROCE | 17.15% | ||
| ROIC | 14.1% | ||
| ROICexc | 15.14% | ||
| ROICexgc | 76.66% | ||
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% | ||
| FCFM | 16.62% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 58.81% | ||
| Cap/Sales | 7.18% | ||
| Interest Coverage | 9.49 | ||
| Cash Conversion | 65.63% | ||
| Profit Quality | 117.58% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 4.95 |
F-Score9
WACC8.83%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y14.19%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%